APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Growth Hormone Deficiency (Ghd) Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human Growth Hormone Deficiency (Ghd) Drug Market Outlook and Growth Opportunities 2026

30 December 2025208 pages

Choose your research edition.

Industry ResearchHuman Growth Hormone Deficiency (Ghd) Drug Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Growth Hormone Deficiency (Ghd) Drug Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Human Growth Hormone Deficiency (Ghd) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Growth Hormone Deficiency (Ghd) Drug Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Growth Hormone Deficiency (Ghd) Drug Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Human Growth Hormone Deficiency (Ghd) Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human Growth Hormone Deficiency (Ghd) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Growth Hormone Deficiency (Ghd) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Growth Hormone Deficiency (Ghd) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human Growth Hormone Deficiency (Ghd) Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human Growth Hormone Deficiency (Ghd) Drug market include Teva Pharmaceutical Industries, Ltd, Merck KGaA, Eli Lilly and Company, Versartis Inc., Strongbridge Biopharma, Sandoz International GmbH (Novartis AG), Pfizer Inc, Opko Health, Inc. and Novo Nordisk A/S, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Human Growth Hormone Deficiency (Ghd) Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Growth Hormone Deficiency (Ghd) Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Growth Hormone Deficiency (Ghd) Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Growth Hormone Deficiency (Ghd) Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Growth Hormone Deficiency (Ghd) Drug Segment by Company

Teva Pharmaceutical Industries, Ltd

Merck KGaA

Eli Lilly and Company

Versartis Inc.

Strongbridge Biopharma

Sandoz International GmbH (Novartis AG)

Pfizer Inc

Opko Health, Inc.

Novo Nordisk A/S

LG Life Sciences

Ipsen S.A.

GeneScience Pharmaceuticals Co. Ltd

Genentech, Inc (Roche)

Ferring Pharmaceuticals

EMD Serono Inc.

Ascendis Pharma A/S

AnkeBio Co. Ltd

Human Growth Hormone Deficiency (Ghd) Drug Segment by Type

Somavaratan

Somapacitan

TransCon-hGH

Others

Human Growth Hormone Deficiency (Ghd) Drug Segment by Application

Children

Adults

Human Growth Hormone Deficiency (Ghd) Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Human Growth Hormone Deficiency (Ghd) Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Human Growth Hormone Deficiency (Ghd) Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Growth Hormone Deficiency (Ghd) Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Human Growth Hormone Deficiency (Ghd) Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Growth Hormone Deficiency (Ghd) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Growth Hormone Deficiency (Ghd) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Growth Hormone Deficiency (Ghd) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Growth Hormone Deficiency (Ghd) Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Growth Hormone Deficiency (Ghd) Drug industry.

Chapter 3: Detailed analysis of Human Growth Hormone Deficiency (Ghd) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Human Growth Hormone Deficiency (Ghd) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Human Growth Hormone Deficiency (Ghd) Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Growth Hormone Deficiency (Ghd) Drug Industry Trends Table 2. Human Growth Hormone Deficiency (Ghd) Drug Industry Drivers Table 3. Human Growth Hormone Deficiency (Ghd) Drug Industry Opportunities and Challenges Table 4. Human Growth Hormone Deficiency (Ghd) Drug Industry Restraints Table 5. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Growth Hormone Deficiency (Ghd) Drug Revenue Share by Company (2021-2026) Table 7. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume Share by Company (2021-2026) Table 9. Global Human Growth Hormone Deficiency (Ghd) Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Human Growth Hormone Deficiency (Ghd) Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Human Growth Hormone Deficiency (Ghd) Drug Key Company Manufacturing Base & Headquarters Table 12. Global Human Growth Hormone Deficiency (Ghd) Drug Company, Product Type & Application Table 13. Global Human Growth Hormone Deficiency (Ghd) Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Growth Hormone Deficiency (Ghd) Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Somavaratan Table 18. Significant Companies of Somapacitan Table 19. Significant Companies of TransCon-hGH Table 20. Significant Companies of Others Table 21. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume Share by Type (2021-2026) Table 25. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume Share by Type (2027-2032) Table 26. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type (2021-2026) Table 30. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Children Table 32. Significant Companies of Adults Table 33. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume Share by Application (2021-2026) Table 37. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume Share by Application (2027-2032) Table 38. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application (2021-2026) Table 42. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application (2027-2032) Table 43. Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Region (2021-2026) & (K Units) Table 45. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share by Region (2021-2026) Table 46. Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Region (2027-2032) & (K Units) Table 47. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share by Region (2027-2032) Table 48. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Region (2021-2026) Table 51. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Region (2027-2032) Table 53. Global Human Growth Hormone Deficiency (Ghd) Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Human Growth Hormone Deficiency (Ghd) Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Country (2021-2026) & (K Units) Table 58. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share by Country (2021-2026) Table 59. Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Country (2027-2032) & (K Units) Table 60. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share by Country (2027-2032) Table 61. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value Market Share by Country (2021-2026) Table 63. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value Market Share by Country (2027-2032) Table 65. Teva Pharmaceutical Industries, Ltd Company Information Table 66. Teva Pharmaceutical Industries, Ltd Business Overview Table 67. Teva Pharmaceutical Industries, Ltd Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Teva Pharmaceutical Industries, Ltd Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 69. Teva Pharmaceutical Industries, Ltd Recent Development Table 70. Merck KGaA Company Information Table 71. Merck KGaA Business Overview Table 72. Merck KGaA Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Merck KGaA Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 74. Merck KGaA Recent Development Table 75. Eli Lilly and Company Company Information Table 76. Eli Lilly and Company Business Overview Table 77. Eli Lilly and Company Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Eli Lilly and Company Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 79. Eli Lilly and Company Recent Development Table 80. Versartis Inc. Company Information Table 81. Versartis Inc. Business Overview Table 82. Versartis Inc. Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Versartis Inc. Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 84. Versartis Inc. Recent Development Table 85. Strongbridge Biopharma Company Information Table 86. Strongbridge Biopharma Business Overview Table 87. Strongbridge Biopharma Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Strongbridge Biopharma Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 89. Strongbridge Biopharma Recent Development Table 90. Sandoz International GmbH (Novartis AG) Company Information Table 91. Sandoz International GmbH (Novartis AG) Business Overview Table 92. Sandoz International GmbH (Novartis AG) Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Sandoz International GmbH (Novartis AG) Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 94. Sandoz International GmbH (Novartis AG) Recent Development Table 95. Pfizer Inc Company Information Table 96. Pfizer Inc Business Overview Table 97. Pfizer Inc Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Pfizer Inc Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 99. Pfizer Inc Recent Development Table 100. Opko Health, Inc. Company Information Table 101. Opko Health, Inc. Business Overview Table 102. Opko Health, Inc. Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Opko Health, Inc. Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 104. Opko Health, Inc. Recent Development Table 105. Novo Nordisk A/S Company Information Table 106. Novo Nordisk A/S Business Overview Table 107. Novo Nordisk A/S Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Novo Nordisk A/S Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 109. Novo Nordisk A/S Recent Development Table 110. LG Life Sciences Company Information Table 111. LG Life Sciences Business Overview Table 112. LG Life Sciences Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. LG Life Sciences Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 114. LG Life Sciences Recent Development Table 115. Ipsen S.A. Company Information Table 116. Ipsen S.A. Business Overview Table 117. Ipsen S.A. Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Ipsen S.A. Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 119. Ipsen S.A. Recent Development Table 120. GeneScience Pharmaceuticals Co. Ltd Company Information Table 121. GeneScience Pharmaceuticals Co. Ltd Business Overview Table 122. GeneScience Pharmaceuticals Co. Ltd Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. GeneScience Pharmaceuticals Co. Ltd Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 124. GeneScience Pharmaceuticals Co. Ltd Recent Development Table 125. Genentech, Inc (Roche) Company Information Table 126. Genentech, Inc (Roche) Business Overview Table 127. Genentech, Inc (Roche) Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Genentech, Inc (Roche) Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 129. Genentech, Inc (Roche) Recent Development Table 130. Ferring Pharmaceuticals Company Information Table 131. Ferring Pharmaceuticals Business Overview Table 132. Ferring Pharmaceuticals Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Ferring Pharmaceuticals Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 134. Ferring Pharmaceuticals Recent Development Table 135. EMD Serono Inc. Company Information Table 136. EMD Serono Inc. Business Overview Table 137. EMD Serono Inc. Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. EMD Serono Inc. Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 139. EMD Serono Inc. Recent Development Table 140. Ascendis Pharma A/S Company Information Table 141. Ascendis Pharma A/S Business Overview Table 142. Ascendis Pharma A/S Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Ascendis Pharma A/S Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 144. Ascendis Pharma A/S Recent Development Table 145. AnkeBio Co. Ltd Company Information Table 146. AnkeBio Co. Ltd Business Overview Table 147. AnkeBio Co. Ltd Human Growth Hormone Deficiency (Ghd) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. AnkeBio Co. Ltd Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio Table 149. AnkeBio Co. Ltd Recent Development Table 150. Key Raw Materials Table 151. Raw Materials Key Suppliers Table 152. Human Growth Hormone Deficiency (Ghd) Drug Distributors List Table 153. Human Growth Hormone Deficiency (Ghd) Drug Customers List Table 154. Research Programs/Design for This Report Table 155. Authors List of This Report Table 156. Secondary Sources Table 157. Primary Sources List of Figures Figure 1. Human Growth Hormone Deficiency (Ghd) Drug Product Image Figure 2. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Human Growth Hormone Deficiency (Ghd) Drug Sales (2021-2032) & (K Units) Figure 5. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Human Growth Hormone Deficiency (Ghd) Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Somavaratan Image Figure 10. Somapacitan Image Figure 11. TransCon-hGH Image Figure 12. Others Image Figure 13. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume Share by Type (2021-2032) Figure 16. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type (2021-2032) Figure 19. Children Image Figure 20. Adults Image Figure 21. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume Share by Application (2021-2032) Figure 24. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application (2021-2032) Figure 27. Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Human Growth Hormone Deficiency (Ghd) Drug Sales Value (2021-2032) & (US$ Million) Figure 32. North America Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Human Growth Hormone Deficiency (Ghd) Drug Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Human Growth Hormone Deficiency (Ghd) Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Human Growth Hormone Deficiency (Ghd) Drug Sales Value (2021-2032) & (US$ Million) Figure 38. South America Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Human Growth Hormone Deficiency (Ghd) Drug Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Human Growth Hormone Deficiency (Ghd) Drug Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Human Growth Hormone Deficiency (Ghd) Drug Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Somavaratan
  • Somapacitan
  • TransCon-hGH
  • Others
Applications
  • Children
  • Adults
Companies covered
  • Teva Pharmaceutical Industries, Ltd
  • Merck KGaA
  • Eli Lilly and Company
  • Versartis Inc.
  • Strongbridge Biopharma
  • Sandoz International GmbH (Novartis AG)
  • Pfizer Inc
  • Opko Health, Inc.
  • Novo Nordisk A/S
  • LG Life Sciences
  • Ipsen S.A.
  • GeneScience Pharmaceuticals Co. Ltd
  • Genentech, Inc (Roche)
  • Ferring Pharmaceuticals
  • EMD Serono Inc.
  • Ascendis Pharma A/S
  • AnkeBio Co. Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value (2021-2032)
  4. 1.2.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Human Growth Hormone Deficiency (Ghd) Drug Market Dynamics
  1. 2.1 Human Growth Hormone Deficiency (Ghd) Drug Industry Trends
  2. 2.2 Human Growth Hormone Deficiency (Ghd) Drug Industry Drivers
  3. 2.3 Human Growth Hormone Deficiency (Ghd) Drug Industry Opportunities and Challenges
  4. 2.4 Human Growth Hormone Deficiency (Ghd) Drug Industry Restraints
3 Human Growth Hormone Deficiency (Ghd) Drug Market by Company
  1. 3.1 Global Human Growth Hormone Deficiency (Ghd) Drug Company Revenue Ranking in 2025
  2. 3.2 Global Human Growth Hormone Deficiency (Ghd) Drug Revenue by Company (2021-2026)
  3. 3.3 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Human Growth Hormone Deficiency (Ghd) Drug Average Price by Company (2021-2026)
  5. 3.5 Global Human Growth Hormone Deficiency (Ghd) Drug Company Ranking (2024-2026)
  6. 3.6 Global Human Growth Hormone Deficiency (Ghd) Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Human Growth Hormone Deficiency (Ghd) Drug Company Product Type and Application
  8. 3.8 Global Human Growth Hormone Deficiency (Ghd) Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Human Growth Hormone Deficiency (Ghd) Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Human Growth Hormone Deficiency (Ghd) Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Human Growth Hormone Deficiency (Ghd) Drug Market by Type
  1. 4.1 Human Growth Hormone Deficiency (Ghd) Drug Type Introduction
  2. 4.1.1 Somavaratan
  3. 4.1.2 Somapacitan
  4. 4.1.3 TransCon-hGH
  5. 4.1.4 Others
  6. 4.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume by Type
  7. 4.2.1 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Type
  11. 4.3.1 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Type (2021-2032)
  13. 4.3.3 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type (2021-2032)
5 Human Growth Hormone Deficiency (Ghd) Drug Market by Application
  1. 5.1 Human Growth Hormone Deficiency (Ghd) Drug Application Introduction
  2. 5.1.1 Children
  3. 5.1.2 Adults
  4. 5.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume by Application
  5. 5.2.1 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Application
  9. 5.3.1 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Application (2021-2032)
  11. 5.3.3 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application (2021-2032)
6 Human Growth Hormone Deficiency (Ghd) Drug Regional Sales and Value Analysis
  1. 6.1 Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Region (2027-2032)
  5. 6.3 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Human Growth Hormone Deficiency (Ghd) Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Human Growth Hormone Deficiency (Ghd) Drug Sales Value (2021-2032)
  12. 6.6.2 North America Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Human Growth Hormone Deficiency (Ghd) Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Human Growth Hormone Deficiency (Ghd) Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Human Growth Hormone Deficiency (Ghd) Drug Sales Value (2021-2032)
  21. 6.9.2 South America Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Human Growth Hormone Deficiency (Ghd) Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Country, 2025 VS 2032
7 Human Growth Hormone Deficiency (Ghd) Drug Country-level Sales and Value Analysis
  1. 7.1 Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales by Country (2027-2032)
  6. 7.4 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Human Growth Hormone Deficiency (Ghd) Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Human Growth Hormone Deficiency (Ghd) Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries, Ltd
  2. 8.1.1 Teva Pharmaceutical Industries, Ltd Company Information
  3. 8.1.2 Teva Pharmaceutical Industries, Ltd Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries, Ltd Human Growth Hormone Deficiency (Ghd) Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries, Ltd Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries, Ltd Recent Developments
  7. 8.2 Merck KGaA
  8. 8.2.1 Merck KGaA Company Information
  9. 8.2.2 Merck KGaA Business Overview
  10. 8.2.3 Merck KGaA Human Growth Hormone Deficiency (Ghd) Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck KGaA Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  12. 8.2.5 Merck KGaA Recent Developments
  13. 8.3 Eli Lilly and Company
  14. 8.3.1 Eli Lilly and Company Company Information
  15. 8.3.2 Eli Lilly and Company Business Overview
  16. 8.3.3 Eli Lilly and Company Human Growth Hormone Deficiency (Ghd) Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly and Company Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  18. 8.3.5 Eli Lilly and Company Recent Developments
  19. 8.4 Versartis Inc.
  20. 8.4.1 Versartis Inc. Company Information
  21. 8.4.2 Versartis Inc. Business Overview
  22. 8.4.3 Versartis Inc. Human Growth Hormone Deficiency (Ghd) Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Versartis Inc. Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  24. 8.4.5 Versartis Inc. Recent Developments
  25. 8.5 Strongbridge Biopharma
  26. 8.5.1 Strongbridge Biopharma Company Information
  27. 8.5.2 Strongbridge Biopharma Business Overview
  28. 8.5.3 Strongbridge Biopharma Human Growth Hormone Deficiency (Ghd) Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Strongbridge Biopharma Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  30. 8.5.5 Strongbridge Biopharma Recent Developments
  31. 8.6 Sandoz International GmbH (Novartis AG)
  32. 8.6.1 Sandoz International GmbH (Novartis AG) Company Information
  33. 8.6.2 Sandoz International GmbH (Novartis AG) Business Overview
  34. 8.6.3 Sandoz International GmbH (Novartis AG) Human Growth Hormone Deficiency (Ghd) Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sandoz International GmbH (Novartis AG) Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  36. 8.6.5 Sandoz International GmbH (Novartis AG) Recent Developments
  37. 8.7 Pfizer Inc
  38. 8.7.1 Pfizer Inc Company Information
  39. 8.7.2 Pfizer Inc Business Overview
  40. 8.7.3 Pfizer Inc Human Growth Hormone Deficiency (Ghd) Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Inc Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  42. 8.7.5 Pfizer Inc Recent Developments
  43. 8.8 Opko Health, Inc.
  44. 8.8.1 Opko Health, Inc. Company Information
  45. 8.8.2 Opko Health, Inc. Business Overview
  46. 8.8.3 Opko Health, Inc. Human Growth Hormone Deficiency (Ghd) Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Opko Health, Inc. Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  48. 8.8.5 Opko Health, Inc. Recent Developments
  49. 8.9 Novo Nordisk A/S
  50. 8.9.1 Novo Nordisk A/S Company Information
  51. 8.9.2 Novo Nordisk A/S Business Overview
  52. 8.9.3 Novo Nordisk A/S Human Growth Hormone Deficiency (Ghd) Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Novo Nordisk A/S Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  54. 8.9.5 Novo Nordisk A/S Recent Developments
  55. 8.10 LG Life Sciences
  56. 8.10.1 LG Life Sciences Company Information
  57. 8.10.2 LG Life Sciences Business Overview
  58. 8.10.3 LG Life Sciences Human Growth Hormone Deficiency (Ghd) Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 LG Life Sciences Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  60. 8.10.5 LG Life Sciences Recent Developments
  61. 8.11 Ipsen S.A.
  62. 8.11.1 Ipsen S.A. Company Information
  63. 8.11.2 Ipsen S.A. Business Overview
  64. 8.11.3 Ipsen S.A. Human Growth Hormone Deficiency (Ghd) Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Ipsen S.A. Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  66. 8.11.5 Ipsen S.A. Recent Developments
  67. 8.12 GeneScience Pharmaceuticals Co. Ltd
  68. 8.12.1 GeneScience Pharmaceuticals Co. Ltd Company Information
  69. 8.12.2 GeneScience Pharmaceuticals Co. Ltd Business Overview
  70. 8.12.3 GeneScience Pharmaceuticals Co. Ltd Human Growth Hormone Deficiency (Ghd) Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 GeneScience Pharmaceuticals Co. Ltd Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  72. 8.12.5 GeneScience Pharmaceuticals Co. Ltd Recent Developments
  73. 8.13 Genentech, Inc (Roche)
  74. 8.13.1 Genentech, Inc (Roche) Company Information
  75. 8.13.2 Genentech, Inc (Roche) Business Overview
  76. 8.13.3 Genentech, Inc (Roche) Human Growth Hormone Deficiency (Ghd) Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Genentech, Inc (Roche) Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  78. 8.13.5 Genentech, Inc (Roche) Recent Developments
  79. 8.14 Ferring Pharmaceuticals
  80. 8.14.1 Ferring Pharmaceuticals Company Information
  81. 8.14.2 Ferring Pharmaceuticals Business Overview
  82. 8.14.3 Ferring Pharmaceuticals Human Growth Hormone Deficiency (Ghd) Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Ferring Pharmaceuticals Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  84. 8.14.5 Ferring Pharmaceuticals Recent Developments
  85. 8.15 EMD Serono Inc.
  86. 8.15.1 EMD Serono Inc. Company Information
  87. 8.15.2 EMD Serono Inc. Business Overview
  88. 8.15.3 EMD Serono Inc. Human Growth Hormone Deficiency (Ghd) Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 EMD Serono Inc. Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  90. 8.15.5 EMD Serono Inc. Recent Developments
  91. 8.16 Ascendis Pharma A/S
  92. 8.16.1 Ascendis Pharma A/S Company Information
  93. 8.16.2 Ascendis Pharma A/S Business Overview
  94. 8.16.3 Ascendis Pharma A/S Human Growth Hormone Deficiency (Ghd) Drug Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Ascendis Pharma A/S Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  96. 8.16.5 Ascendis Pharma A/S Recent Developments
  97. 8.17 AnkeBio Co. Ltd
  98. 8.17.1 AnkeBio Co. Ltd Company Information
  99. 8.17.2 AnkeBio Co. Ltd Business Overview
  100. 8.17.3 AnkeBio Co. Ltd Human Growth Hormone Deficiency (Ghd) Drug Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 AnkeBio Co. Ltd Human Growth Hormone Deficiency (Ghd) Drug Product Portfolio
  102. 8.17.5 AnkeBio Co. Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Growth Hormone Deficiency (Ghd) Drug Value Chain Analysis
  2. 9.1.1 Human Growth Hormone Deficiency (Ghd) Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Growth Hormone Deficiency (Ghd) Drug Sales Mode & Process
  6. 9.2 Human Growth Hormone Deficiency (Ghd) Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Growth Hormone Deficiency (Ghd) Drug Distributors
  9. 9.2.3 Human Growth Hormone Deficiency (Ghd) Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst